Cellectis Sa Stock Analysis
| CMVLF Stock | USD 4.40 0.00 0.00% |
Cellectis SA holds a debt-to-equity ratio of 0.52. Cellectis' financial risk is the risk to Cellectis stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Cellectis' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Cellectis' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Cellectis Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Cellectis' stakeholders.
For many companies, including Cellectis, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Cellectis SA, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Cellectis' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Cellectis' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Cellectis is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Cellectis to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Cellectis is said to be less leveraged. If creditors hold a majority of Cellectis' assets, the Company is said to be highly leveraged.
Cellectis SA is fairly valued with Real Value of 4.56 and Hype Value of 4.4. The main objective of Cellectis pink sheet analysis is to determine its intrinsic value, which is an estimate of what Cellectis SA is worth, separate from its market price. There are two main types of Cellectis' stock analysis: fundamental analysis and technical analysis.
The Cellectis pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cellectis' ongoing operational relationships across important fundamental and technical indicators.
Cellectis |
Cellectis Pink Sheet Analysis Notes
The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cellectis SA recorded a loss per share of 2.95. The entity had not issued any dividends in recent years. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis Romainvil operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 294 people.The quote for Cellectis SA is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Cellectis SA please contact Andre Choulika at 33 1 81 69 16 00 or go to https://www.cellectis.com.Cellectis SA Investment Alerts
| Cellectis SA generated a negative expected return over the last 90 days | |
| The company reported the revenue of 57.29 M. Net Loss for the year was (114.2 M) with profit before overhead, payroll, taxes, and interest of 34.18 M. | |
| Cellectis SA has accumulated about 153.13 M in cash with (104.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37. |
Cellectis Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 131.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cellectis's market, we take the total number of its shares issued and multiply it by Cellectis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 13th of February 2026, Cellectis shows the Mean Deviation of 0.3801, risk adjusted performance of (0.11), and Standard Deviation of 1.34. Cellectis SA technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cellectis SA standard deviation and maximum drawdown to decide if Cellectis SA is priced correctly, providing market reflects its regular price of 4.4 per share. Given that Cellectis has variance of 1.8, we suggest you to validate Cellectis SA's prevailing market performance to make sure the company can sustain itself at a future point.Cellectis SA Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Cellectis price series with the more recent values given greater weights.
Cellectis Predictive Daily Indicators
Cellectis intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cellectis pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cellectis Forecast Models
Cellectis' time-series forecasting models are one of many Cellectis' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cellectis' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Cellectis SA Debt to Cash Allocation
Many companies such as Cellectis, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Cellectis SA has accumulated 18.77 M in total debt with debt to equity ratio (D/E) of 0.52, which is about average as compared to similar companies. Cellectis SA has a current ratio of 3.11, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cellectis until it has trouble settling it off, either with new capital or with free cash flow. So, Cellectis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cellectis SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cellectis to invest in growth at high rates of return. When we think about Cellectis' use of debt, we should always consider it together with cash and equity.Cellectis Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Cellectis' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Cellectis, which in turn will lower the firm's financial flexibility.About Cellectis Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Cellectis prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cellectis shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Cellectis. By using and applying Cellectis Pink Sheet analysis, traders can create a robust methodology for identifying Cellectis entry and exit points for their positions.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis Romainvil operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 294 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Cellectis to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Complementary Tools for Cellectis Pink Sheet analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |